<li id="tt94p"><dl id="tt94p"><video id="tt94p"></video></dl></li>

<span id="tt94p"></span>

<rt id="tt94p"></rt>

We are experiencing some temporary issues. The market data on this page is currently delayed. Please bear with us as we address this and restore your personalized lists.

NasdaqCM - Delayed Quote USD

Vivos Therapeutics, Inc. (VVOS)

2.5300

+0.2200

(+9.52%)

At close: October 11 at 4:00 PM EDT

2.5200

-0.01

(-0.40%)

After hours: October 11 at 4:30 PM EDT

Key Events

Loading Chart for VVOS

9/21 12:03 PM

DELL

Previous Close 2.3100
Open 2.3016
Bid 2.5100 x 100
Ask 2.5700 x 100
Day's Range 2.3016 - 2.5300
52 Week Range 1.9100 - 48.7900
Volume 84,808
Avg. Volume 1,332,818
Market Cap (intraday) 12.056M
Beta (5Y Monthly) 7.69
PE Ratio (TTM) --
EPS (TTM) -6.8000
Earnings Date Nov 12, 2024 - Nov 18, 2024
Forward Dividend & Yield --
Ex-Dividend Date --
1y Target Est 7.42

Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado.

114

Full Time Employees

December 31

Fiscal Year Ends

Sector

Medical Devices

Industry

Vivos Therapeutics Granted CPT? Coverage and Reimbursement Codes for All Vivos CARE Oral Medical Devices From American Medical Association

Vivos Therapeutics Granted CPT? Coverage and Reimbursement Codes for All Vivos CARE Oral Medical Devices From American Medical Association

Vivos Therapeutics Announces Pricing of $4.3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

Vivos Therapeutics Announces Pricing of $4.3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

Vivos Therapeutics Says It Is Poised To Disrupt Pediatric Sleep Apnea Market, Secures FDA Approval For DNA Appliance To Treat Snoring In Children

Vivos Therapeutics Says It Is Poised To Disrupt Pediatric Sleep Apnea Market, Secures FDA Approval For DNA Appliance To Treat Snoring In Children

Vivos Therapeutics Receives Groundbreaking FDA 510(k) Clearance to Treat Moderate to Severe Pediatric Sleep Apnea and Snoring

Vivos Therapeutics Receives Groundbreaking FDA 510(k) Clearance to Treat Moderate to Severe Pediatric Sleep Apnea and Snoring

Vivos Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update

Vivos Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update

Vivos Therapeutics Schedules Release of Second Quarter 2024 Financial Results and Conference Call

Vivos Therapeutics Schedules Release of Second Quarter 2024 Financial Results and Conference Call

Vivos eyes human trials for radiation treatment gel with IDE submission

Vivos eyes human trials for radiation treatment gel with IDE submission

Vivos Therapeutics Announces Positive Results From 7-Month Multi-Site Pilot of its New Provider-Based Marketing and Distribution Model

Vivos Therapeutics Announces Positive Results From 7-Month Multi-Site Pilot of its New Provider-Based Marketing and Distribution Model

Vivos Therapeutics Closes $7.5 Million At-The-Market Private Equity-Backed Investment and Launches Strategic Marketing and Distribution Alliance

Vivos Therapeutics Closes $7.5 Million At-The-Market Private Equity-Backed Investment and Launches Strategic Marketing and Distribution Alliance

Consolidated Water Comments on ISS and Glass Lewis Reports and Urges Stockholders to Vote “FOR” Re-Election of Its Highly Qualified Directors

Consolidated Water Comments on ISS and Glass Lewis Reports and Urges Stockholders to Vote “FOR” Re-Election of Its Highly Qualified Directors

Vivos Therapeutics Inc (VVOS) Q1 2024 Earnings Call Transcript Highlights: Navigating ...

Trailing total returns as of 10/11/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

VVOS

79.66%

S&P 500

21.91%

1-Year Return

VVOS

66.60%

S&P 500

33.43%

3-Year Return

VVOS

97.31%

S&P 500

32.42%

5-Year Return

VVOS

98.57%

S&P 500

58.73%

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Vivos Therapeutics, Inc.

2.5300

+9.52%

Mkt Cap 12.056M

Industry Medical Devices

Bone Biologics Corporation

1.6700

-0.60%

Mkt Cap 3.502M

Industry Medical Devices

Tenon Medical, Inc.

3.5600

-1.11%

Mkt Cap 2.012M

Industry Medical Devices

Intelligent Bio Solutions Inc.

1.4900

+1.36%

Mkt Cap 6.332M

Industry Medical Devices

ReShape Lifesciences Inc.

5.08

+0.99%

Mkt Cap 2.574M

Industry Medical Devices

Tivic Health Systems, Inc.

0.2380

-5.18%

Mkt Cap 1.472M

Industry Medical Devices

1.6650

+19.78%

Mkt Cap 3.108M

Industry Medical Devices

Telesis Bio, Inc.

2.7600

-2.82%

Mkt Cap 4.893M

Industry Medical Devices

Heart Test Laboratories, Inc.

3.3800

-13.78%

Mkt Cap 3.089M

Industry Medical Devices

Nexalin Technology, Inc.

0.7810

+22.80%

Mkt Cap 8.268M

Industry Medical Devices

Sintx Technologies, Inc.

3.1800

+0.63%

Mkt Cap 2.376M

Industry Medical Devices

Valuation Measures

    Annual 

As of 10/11/2024

Market Cap

12.06M
Enterprise Value

6.92M
Trailing P/E

--
Forward P/E

--
PEG Ratio (5yr expected)

--
Price/Sales (ttm)

0.37
Price/Book (mrq)

1.90
Enterprise Value/Revenue

0.49
Enterprise Value/EBITDA

--

Financial Highlights

Profitability and Income Statement

Profit Margin

-85.90%
Return on Assets (ttm)

-57.00%
Return on Equity (ttm)

-284.96%
Revenue (ttm)

14.02M
Net Income Avi to Common (ttm)

-12.04M
Diluted EPS (ttm)

-6.8000

Balance Sheet and Cash Flow

Total Cash (mrq)

6.9M
Total Debt/Equity (mrq)

27.79%
Levered Free Cash Flow (ttm)

-8.9M

Earnings Per Share

Consensus EPS

Revenue vs. Earnings

Revenue 4.05M

Earnings -1.93M

Analyst Recommendations

Strong Buy
Buy
Hold
Underperform
Sell

Analyst Price Targets

6.60

7.42 Average

2.5300 Current

8.25 High

VVOS does not have Company Insights

ABVC ABVC BioPharma, Inc.

0.4720

-2.48%

VRPX Virpax Pharmaceuticals, Inc.

0.4710

+1.84%

RNAZ TransCode Therapeutics, Inc.

0.7000

-4.03%

ADTX Aditxt, Inc.

1.1600

-5.69%

PALI Palisade Bio, Inc.

3.4050

+0.15%

TPST Tempest Therapeutics, Inc.

1.0250

-6.82%

ENSC Ensysce Biosciences, Inc.

0.1778

-4.41%

SNOA Sonoma Pharmaceuticals, Inc.

3.1050

+3.50%

MINM Minim, Inc.

1.7500

+2.34%

NRBO NeuroBo Pharmaceuticals, Inc.

2.5600

+3.64%

PTPI Petros Pharmaceuticals, Inc.

0.3150

-0.16%

PBLA Panbela Therapeutics, Inc.

0.3550

+4.41%

DRMA Dermata Therapeutics, Inc.

1.3500

+0.75%

PRFX PainReform Ltd.

0.5830

-9.08%

NEXI NexImmune, Inc.

0.2160

+0.05%

SCPS Scopus BioPharma Inc.

0.0003

0.00%

<li id="d7nrz"><dl id="d7nrz"></dl></li>